EP0259425A1 - Conservation de proteines - Google Patents

Conservation de proteines

Info

Publication number
EP0259425A1
EP0259425A1 EP19870901561 EP87901561A EP0259425A1 EP 0259425 A1 EP0259425 A1 EP 0259425A1 EP 19870901561 EP19870901561 EP 19870901561 EP 87901561 A EP87901561 A EP 87901561A EP 0259425 A1 EP0259425 A1 EP 0259425A1
Authority
EP
European Patent Office
Prior art keywords
polyhydroxy compound
water
protein
process according
haemoglobin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP19870901561
Other languages
German (de)
English (en)
Inventor
James Arthur Hayward
David Samuel Johnston
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Abbott Vascular Devices Ltd
Original Assignee
Biocompatibles Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biocompatibles Ltd filed Critical Biocompatibles Ltd
Publication of EP0259425A1 publication Critical patent/EP0259425A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length

Definitions

  • the present invention relates to a method of dry storage which now permits the long-term preservation of materials such as haemoglobin, erythrocyes, liposomes and cells.
  • Oxidation of the iron atom of the haem prosthetic group from 2+ to the 3+ state converts oxy- or deoxyhaemoglobin to the biologically nonfunctional methaemoglobin.
  • the reaction is promoted by conditions of low oxygen tension and is minimised i n vivo by the presence of potent reducing systems operating in the cytoplasm of intact erythrocytes.
  • erythrocytes are obtained from human donors for transfusion, their storage ex vivo is limited, in part, by the accelerated formation of oxidised haem (methaemoglobin).
  • the present invention therefore provides a process for preserving a material having a water-dependant structure comprising contacting the material with an aqueous solution of a polyhydroxy compound then removing water from the material.
  • material having a water-dependant structure it is intended to encompass such materials as proteins, liposomes and cells which have secondary, tertiary or quaternary structure determined by hydrophobic and/or hydrophilic interactions in the presence of water which structure is irreversibly altered or partially or completely destroyed by removal of the water.
  • polyhydroxy compound it is intended to encompass any material having two or more hydroxy groups per molecule which is capable of hydrogen bonding to, or otherwise stabilising, a material having a water-dependant structure.
  • Suitable polyhydroxy compounds include sugars and similar or related polyols, especially trioses, pentoses and hexoses, mono-, di or oligosaccharides and related polyols.
  • Preferred polyhydroxy compounds are glucose, galactose and non-reducing sugars especially trehalose.
  • the present invention in a particular embodiment also provides a process for preserving a material having a water-dependant structure which encapsulates one or more spaces containing aqueous solutions or suspensions which comprises contacting the material with, and introducing into one or more encapsulated spaces therein, an aqueous solution of polyhydroxy compound then removing water from the material.
  • the present invention in another aspect provides a dry formulation comprising a material having a water-dependant structure and a polyhydroxy compound.
  • the polyhydroxy compound will be in intimate admixture with the material having a water-dependant structure and, in the case where the material encapsulates one or more spaces containing the residue of aqueous solutions or suspensions, preferably the polyhydroxy compound is also dispersed within those spaces.
  • the preservation process of the present invention is particularly suitable for the storage of haemoglobin with minimal oxidation of the heme-iron and with retention of gas-transporting capacity upon rehydration.
  • the dry haemoglobin may be prepared from simple aqueous solutions of purified haemoglobin, from erythrocyte lysates, from intact erythrocytes or from erythrocyte surrogates (haemosomes).
  • Hydrophobic structures such as the membranes which delimit all cells and their organelles, arise by the expulsion of water from their non-polar parts.
  • Hydrophilic structures such as globular proteins are stabilised by hydrogen-bonding with water in solution and by the maintenance of specific dipoles in a medium of specific dielectric constant.
  • anhydrobiosis In recent years the ability to survive desiccation, now termed “anhydrobiosis”, has been shown to be a property of a small but diverse group of organisms including fungal spores, macrocysts of the slime mold Dictyostelium, baker's yeast, brine shrimp cysts, nematodes and plant seeds (for review see Crowe and Crowe, 1984) .
  • Trehalose a non-reduc ing d isacchar ide of glucose that is distributed widely in nature, has been found at particularly high concentrations (as much as 20% of the dry weight) in several of the organisms capable of anhydrobiosis.
  • the survival of dehydration by some organisms is correlated with the synthesis of trehalose during dehydration (Madin and Crowe, 1975) or its degradation following rehydration (Clegg. 1964).
  • This molecule was implicated in the "water replacement hypothesis", which suggested that the hydroxyl groups of simple carbohydrates might replace the hydration shell of the polar head groups of phosopholipids that is lost during dehydration (Crowe and Clegg, 1973) .
  • a particularly novel extension of our invention concerns the stabilisation of dehydrated cells and their surrogates. It is possible to transiently produce pores in both biological and artificial membrane which spontaneously reseal. During the time course of their existence. however, these pores are of sufficient diameter to permit the entry of carbohydrates into the cytoplasm (cells) or encapsulated volume (liposomes). Thus, it should be possible to introduce trehalose (or other carbohydrates) into the cytoplasm of human erythrocytes, enabling their extended storage in the dehydrated state. Autologous red cells could therefore be stored indefinitely for patients at high risk of anaemia. Similarly, haemosomes could be prepared and stored in bulk following dehydration. Application of dry haemosomes would be a simple matter following their rehydration ad hoc.
  • Fig. 1 is a histogram showing Percentages of methaemoglobin formed upon rehydration of haemoglobin powders. Sugars were present at concentrations of 0.25 molar following rehydration; haemoglobin was 0.015 molar.
  • Oxyhaemoglobin without sugar 2) Deoxyhaemoglobin without sugar, and 3) to 11) Oxyhaemoglobin with 3) Arabinose, 4) Glactose, 5) Fucose, 6) Glucose, 7) Mannose, 8) Maltose, 9) lactose, 10) Trehalose and 11) Sucrose.
  • Carbohydrate-protein mixtures were prepared in solution by addition of carbohydrate to the protein dissolved in water or buffer. A variety of trioses, pentoses and hexoses were examined as well as mono- and disacchar ides. Concentrations of the sugars were varied, from 1:1 (weightrweight) up to a maximum of 0.25 molar sugar.
  • Water was removed by one of three methods: a) evaporation, in which the solution is mildly heated under a steady stream of gaseous nitrogen; b) evacuation, in which the sample is exposed to reduced pressure at room temperature, or, c) lyophilisation, in which the solution is first frozen in liquid nitrogen and the water sublimed under high vacuum. Dried samoles were stored for extended period over phosphorus pentoxide in vacuo.
  • Calorimetric evaluation was performed by differential scanning calorimetry (DSC) using Perkin-Elmer DSC-2.
  • the heating rate was 2.5°C/minute and a full-scale deflection on the recorder corresponded to a change in heat flow of 0.25m.cal./sec.
  • the transition temperatures obtained were the temperatures of maximal heat flow.
  • Table 1 contains the denaturation temperatures and denaturation enthalpy and entropy changes of lysozyme dissolved in water and in solutions of either of the sugars glucose, galactose or trehalose.
  • the presence of any of the three sugars increases the denaturation temperature, in general agreement with the observations reported by others (Gerlsma, 1968; Neucere and St. Angelo, 1972).
  • the sugars stabilise the native structure of the protein with respect to the denatured state. This property is exhibited by each of the three sugars examined.
  • the temperatures of maximum heat flow and the enthalpy and entropy changes associated with the transitions for freeze-dried lysozyme in the presence or absence of carbohydrate are outlined in Table 2.
  • the endothermic transition of pure dry lysozyme occurs at a temperature approximately 70°C above the denaturation temperature of the protein in water. In the solid state the polypeptide chains of a protein will be less flexible than in solution at the same temperature.
  • a dry protein will reach the degree of flexibility necessary for unfolding of the protein structure at a higher temperature than a protein in aqueous solution.
  • each of the carbohydrates tested was capable of protecting haemoglobin against oxidative damage.
  • the protective effect was clearly manifest even in those samples that had been stored in the dried state for periods in excess of three months.
  • Rehydrated sugar-haemoglobin mixtures were capable of reversible gas exchange as evidenced by the spectral shifts induced by exposure to oxygen, nitrogen or carbon monoxide.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Dispersion Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Un procédé de conservation d'un matériau ayant une structure hydrosensible consiste à mettre le matériau en contact avec une solution aqueuse d'un composé de polyhydroxy, puis à retirer l'eau du matériau.
EP19870901561 1986-02-28 1987-02-27 Conservation de proteines Withdrawn EP0259425A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB868604983A GB8604983D0 (en) 1986-02-28 1986-02-28 Protein preservation
GB8604983 1986-02-28

Publications (1)

Publication Number Publication Date
EP0259425A1 true EP0259425A1 (fr) 1988-03-16

Family

ID=10593832

Family Applications (1)

Application Number Title Priority Date Filing Date
EP19870901561 Withdrawn EP0259425A1 (fr) 1986-02-28 1987-02-27 Conservation de proteines

Country Status (4)

Country Link
EP (1) EP0259425A1 (fr)
JP (1) JPS63502592A (fr)
GB (1) GB8604983D0 (fr)
WO (1) WO1987005300A2 (fr)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8715238D0 (en) * 1987-06-29 1987-08-05 Quadrant Bioresources Ltd Food process
GB8801338D0 (en) * 1988-01-21 1988-02-17 Quadrant Bioresources Ltd Preservation of viruses
US5045446A (en) * 1988-08-26 1991-09-03 Cryopharm Corporation Lyophilization of cells
US5958670A (en) * 1988-05-18 1999-09-28 Cobe Laboratories, Inc. Method of freezing cells and cell-like materials
ATE107502T1 (de) * 1988-10-05 1994-07-15 Vestar Inc Verfahren zur herstellung von liposomen mit verbesserter stabilität während des trocknens.
US5059518A (en) * 1988-10-20 1991-10-22 Coulter Corporation Stabilized lyophilized mammalian cells and method of making same
US5030560A (en) * 1988-11-04 1991-07-09 Immucor, Inc. Method for drying mammalian cells for use in solid phase immunoassays and articles incorporating same
US5192663A (en) * 1988-11-04 1993-03-09 Immucor, Inc. Article having an organic dye and a monolayer of dried mammalian cells and a method for utilizing the article
USRE39497E1 (en) 1989-02-16 2007-02-27 Nektar Therapeutics Storage of materials
GB8903593D0 (en) 1989-02-16 1989-04-05 Pafra Ltd Storage of materials
FR2645741B1 (fr) * 1989-03-20 1995-06-23 Dior Christian Parfums Procede pour fixer un produit sur la membrane d'un keratinocyte au moyen d'une liaison ligand-recepteur, procede de preparation d'un tel produit, produit obtenu, composition cosmetique ou pharmaceutique le contenant et son procede de preparation
ZA902663B (en) * 1989-04-07 1991-12-24 Syntex Inc Interleukin-1 formulation
IE64738B1 (en) * 1990-03-20 1995-09-06 Akzo Nv Stabilized gonadotropin containing preparations
US5384132A (en) * 1990-03-20 1995-01-24 Akzo N.V. Stabilized gonadotropin containing preparations
US5270057A (en) * 1990-03-20 1993-12-14 Akzo N.V. Stabilized gonadotropin containing preparations
GB9010742D0 (en) * 1990-05-14 1990-07-04 Quadrant Bioresources Ltd Stabilization of biological macromolecular substances
JPH05505680A (ja) * 1991-01-11 1993-08-19 コーブ　ラボラトリーズ　インコーポレイテッド 乾燥または凍結乾燥した細胞または細胞―様物質を使用する循環抗体の型を検定する方法
AU659645B2 (en) 1991-06-26 1995-05-25 Inhale Therapeutic Systems Storage of materials
CA2128527A1 (fr) * 1992-01-21 1993-07-22 Raymond P. Goodrich, Jr. Methode de congelation de cellules et de materiaux de type cellulaire
CZ296649B6 (cs) * 1993-02-23 2006-05-17 Genentech, Inc. Zpusob výroby stabilizovaného polypeptidového prostredku zahrnující stabilizování polypeptidu protidenaturaci organickými rozpoustedly, jeho príprava a prostredek pro regulované uvolnování polypeptidu
DE69420876T2 (de) 1993-03-18 2000-04-20 Terumo Corp Liposom mit eingekapseltem Hämoglobin sowie Verfahren zu dessen Herstellung
US5674528A (en) * 1994-06-15 1997-10-07 Terumo Kabushiki Kaisha Hemoglobin-encapsulated liposome
US6586006B2 (en) 1994-08-04 2003-07-01 Elan Drug Delivery Limited Solid delivery systems for controlled release of molecules incorporated therein and methods of making same
US6290991B1 (en) 1994-12-02 2001-09-18 Quandrant Holdings Cambridge Limited Solid dose delivery vehicle and methods of making same
US6309671B1 (en) 1995-04-14 2001-10-30 Inhale Therapeutic Systems Stable glassy state powder formulations
GB9508691D0 (en) 1995-04-28 1995-06-14 Pafra Ltd Stable compositions
HUP9901716A3 (en) * 1995-06-07 2000-04-28 Quadrant Holdings Cambridge Methods for stably incorporating substances within dry, foamed glass matrices and compositions obtained thereby
US6632648B1 (en) 1996-05-14 2003-10-14 Elan Drug Delivery Limited Methods of terminal sterilization of fibrinogen
US6468782B1 (en) 1996-12-05 2002-10-22 Quadrant Healthcare (Uk) Limited Methods of preserving prokaryotic cells and compositions obtained thereby
DK0967862T3 (da) * 1997-02-07 2003-05-12 Elan Drug Delivery Ltd Fremgangsmåde og præparater til fremstilling af tørrede, lagringsstabile blodplader
US20060165606A1 (en) 1997-09-29 2006-07-27 Nektar Therapeutics Pulmonary delivery particles comprising water insoluble or crystalline active agents
US6770478B2 (en) 2000-02-10 2004-08-03 The Regents Of The University Of California Erythrocytic cells and method for preserving cells
EP1255439A4 (fr) 2000-02-10 2007-01-03 Univ California Plaquettes et procedes therapeutiques
US7871598B1 (en) 2000-05-10 2011-01-18 Novartis Ag Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use
EP1458360B1 (fr) 2001-12-19 2011-05-11 Novartis AG Administration pulmonaire d'aminoglycosides
US8409587B2 (en) * 2002-11-01 2013-04-02 Glaxosmithkline Biologicals S.A. Immunogenic composition
ES2502691B1 (es) * 2013-09-25 2015-07-07 Sani-Red, S.L. Método de conservación y estabilización de proteínas, aplicable para desarrollos industriales de formulaciones de productos sanitarios, farmacéuticos y cosméticos
WO2016209907A1 (fr) 2015-06-25 2016-12-29 The Regents Of The University Of California Films de support stables pour microscopie électronique

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1855591A (en) * 1926-02-03 1932-04-26 Wallerstein Co Inc Invertase preparation and method of making the same
EP0111216A3 (fr) * 1980-03-31 1985-01-16 Takeda Chemical Industries, Ltd. Méthode pour essai immunoenzymatique, conjugué peptide-enzyme, son lyophilisat, anticorps et trousse de réactifs
US4457916A (en) * 1982-08-31 1984-07-03 Asahi Kasei Kogyo Kabushiki Kaisha Method for stabilizing Tumor Necrosis Factor and a stable aqueous solution or powder containing the same
US4880635B1 (en) * 1984-08-08 1996-07-02 Liposome Company Dehydrated liposomes
EP0208764A4 (fr) * 1985-01-11 1987-10-08 Univ California Procede de conservation de liposomes.
JPH0779694B2 (ja) * 1985-07-09 1995-08-30 カドラント バイオリソ−シズ リミテツド 蛋白質および同類品の保護

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO8705300A2 *

Also Published As

Publication number Publication date
GB8604983D0 (en) 1986-04-09
JPS63502592A (ja) 1988-09-29
WO1987005300A2 (fr) 1987-09-11
WO1987005300A3 (fr) 1987-10-22

Similar Documents

Publication Publication Date Title
EP0259425A1 (fr) Conservation de proteines
US5242792A (en) Method for the preservation of red blood cells by lyophilization using glycerol or inositol with disaccharides
JP2809735B2 (ja) 細胞の凍結乾燥法
US4806343A (en) Cryogenic protectant for proteins
CA1197462A (fr) Systeme de transport d'oxygene fonctionnel
US4874690A (en) Lyophilization of red blood cells
US5178884A (en) Lyophilized and reconstituted red blood cell compositions
Crowe et al. Stabilization of dry phospholipid bilayers and proteins by sugars.
KR920002300B1 (ko) 리포좀의 보존방법
IE47165B1 (en) Process for the dehydration of a colloidal dispersion of liposomes
US5690963A (en) Freeze dried red blood cells
US4897353A (en) Cryogenic protection of phosphofructokinase using amino acids and zinc ions
Török et al. Preservation of trehalose-loaded red blood cells by lyophilization
Tan et al. Freeze-drying of fungi: influence of composition and glass transition temperature of the protectant
CN102327289B (zh) 一种注射用红细胞冻干粉制剂及其制备方法
Meldrum The reduction of glutathione in mammalian erythrocytes
US4612370A (en) Lipid-saccharide reaction products
EP0955991A1 (fr) Micro-emulsions a base de lecithine contenant des enzymes proteolytiques et technique d'epilation enzymatique permanente
Johnston et al. The influence of sugars on the properties of freeze-dried lysozyme and haemoglobin
WO1992008478A1 (fr) Procede d'amelioration de la stabilite du stockage a long terme de produits d'hemoglobine
US4954354A (en) Process utilizing alcohol oxidase
JPH02178233A (ja) ヘモグロビン含有リポソームおよびその製法
Nishiya et al. Circular dichroism study of membrane dynamics focused on effect of monosialogangliosides
EP0356258A2 (fr) Procédés de lyophilisation des globules rouges sanguins; support de lyophilisation à cet usage
NEWMAN et al. Carbohydrates in Biopreservation

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19871117

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE FR GB IT LI LU NL SE

17Q First examination report despatched

Effective date: 19900514

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 19900925

RIN1 Information on inventor provided before grant (corrected)

Inventor name: HAYWARD, JAMES, ARTHUR

Inventor name: JOHNSTON, DAVID, SAMUEL